Abstract 832P
Background
Treating pediatric acute B-cell lymphoblastic leukemia (pB-ALL) who experience central nervous system relapses (CNSR) is challenging and often results in high mortality rates. The aim of this study was to develop and validate a predictive model for CNSR in pB-ALL, allowing for early identification and assessment.
Methods
1495 patients of pB-ALL patients from the TARGET database were randomly assigned to a training cohort of 1079 patients and an internal validation cohort of 416 patients. Multi-variable COX regression analysis was applied to construct the model using the training cohort. The validation cohorts comprised of an internal validation cohort and an external validation cohort consisting of Chinese patients. The analysis was conducted using consistency index (C-index), AUROC, Kaplan-Meier curves, calibration curve, and decision curve analysis to evaluate this model.
Results
The prediction model for CNSR in pB-ALL, named CLOMB, was constructed using indicators selected from the training cohort. The model had a C-index of 0.748 and was found to be highly accurate in predicting CNSRs in both the training and validation cohorts, as determined by AUROC measures. A statistically significant difference in event-free survival was observed between pB-ALL patients divided into CNSR high-risk and low-risk groups using the CLOMB calculated risk score of 0.76 as a cut-off value. In the external validation cohort, CLOMB had an AUROC of 0.590, which was significantly higher than MRD on days 19 and days 46.
Conclusions
The newly developed predictive model, CLOMB, has shown strong power and utility in CNS relapse prediction and risk stratification, which may help modify treatment options in clinical routine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
836P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
837P - Expression analysis, clinical significance and potential function of ALOX5AP in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
838P - Bayesian modeling in the survival analysis of patients with multiple myeloma with emphasis on missing data analysis
Presenter: Nelson Cruz Gutierrez
Session: Poster session 09
839P - Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: jianliang yang
Session: Poster session 09
840P - Orelabrutinib-based regimens in chronic lymphocytic leukemia with comorbidities: A real-world study
Presenter: Xun Lai
Session: Poster session 09
841P - Transforming the landscape of pediatric AML treatment: A cutting-edge SCT prognostic model
Presenter: Hua Yang
Session: Poster session 09
Resources:
Abstract
842P - Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment: An analysis of the lymphoma coalition’s 2022 global patient survey
Presenter: Natacha Bolanos Fernandez
Session: Poster session 09
843P - Challenges and insights in treating Langerhans cell histiocytosis: Persistent mutations and novel therapeutic approaches
Presenter: Marzieh NASHVI
Session: Poster session 09
844TiP - Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin)
Presenter: Wanzhuo Xie
Session: Poster session 09
845TiP - CNS lymphoma imaging and molecular biomarkers study: CLIMB
Presenter: Panagiotis Ntellas
Session: Poster session 09